WHAT IS CLAIMED IS:

1. Use of an effective amount of a composition disrupting a genomic sequence encompassing 3'-untranslated region (UTR) of sST2 gene/transcript in the manufacture of a medicament for treating Alzheimer's Disease (AD) or reducing risk of AD, wherein the medicament is to be administered to a person in need thereof.

2. The use of claim 1, further comprising, prior to administration, sequencing at least a portion of the person's genome.

3. The use of claim 1, wherein the person is an *APOE-ε4* carrier or a non-*APOE-ε4* carrier.

4. The use of claim 1, wherein the person is a female or a male.

5. The use of claim 1, wherein the person has been diagnosed with AD, or the person is not yet diagnosed with AD but has known risk factors for AD.

6. The use of claim 1, wherein the composition comprising an siRNA, a microRNA, a miniRNA, a lncRNA, or an antisense oligonucleotide targeting the 3'-UTR of the sST2 gene.

7. The use of claim 1, wherein the composition comprising one or more antisense oligonucleotides listed in Table 9.

8. The use of claim 7, wherein the composition comprises one vector encoding a Cas9 nuclease and two sgRNAs.

9. The use of claim 7 or 8, wherein the one or more vectors are one or more viral vectors.

10. The use of claim 1, wherein the composition is to be administered by subcutaneous, intramuscular, intravenous, intraperitoneal, or intracranial injection or by oral or nasal administration.

11. The use of claim 10, wherein the composition is to be administered in the form of a solution, a suspension, a powder, a paste, a tablet, or a capsule.

12. A kit for treating Alzheimer's Disease (AD) or reducing risk of AD in a person in need thereof, comprising a container containing a composition disrupting a genomic sequence encompassing the 3'-UTR of the sST2 gene.

13. The kit of claim 12, wherein the composition is formulated for subcutaneous, intramuscular, intravenous, intraperitoneal, or intracranial injection, or for oral or nasal administration.

14. The kit of claim 12, wherein the composition comprising an siRNA, a microRNA, a miniRNA, a lncRNA, or an antisense oligonucleotide targeting the genomic sequence encompassing the 3'-UTR of the sST2 gene.

15. The kit of claim 12, wherein the composition comprising one or more antisense oligonucleotides listed in Table 9.

16. The kit of claim 15, wherein the composition comprises one vector encoding a Cas9 nuclease and two sgRNAs.

17. The kit of claim 12, further comprising a second container containing agents for sequencing at least a portion of the person's genome.

18. The kit of claim 12, further comprising an instruction manual for administration of the composition.